Comparing high and standard doses of rifampicin for tuberculosis treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness and safety of an optimized dose of rifampicin (1800 mg) compared to standard doses (450 mg or 600 mg based on weight) in patients with pulmonary tuberculosis. The study will assess the incidence of hepatotoxicity, adverse events, treatment outcomes, and culture conversion rates between the two dosing regimens. Participants will receive the optimized dose daily, and researchers will analyze the pharmacokinetics of both dosing strategies to determine the best approach for treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* The patient has provided informed consent for study participation prior to all trial-related procedures.
* The patient has a diagnosis of pulmonary tuberculosis according to the local diagnostic criteria.
* The patient is aged 18 years or older at the day of informed consent.
* No known allergic reactions or toxicity to rifampicin in the past.
* Female patients of childbearing potential must have a negative serum pregnancy test, and consent to practice an effective method of birth control during the study. And they should not be lactating during the trial (female participants of childbearing potential only). Effective birth control for female patients has to include two methods, including methods that the patient's sexual partner(s) use. At least one must be a barrier method. Female patients are considered not to be of childbearing potential if they are post-menopausal with no menses for the last 12 months, or surgically sterile (this condition is fulfilled by bilateral oophorectomy, hysterectomy, and by tubal ligation which is done at least 12 months prior to enrolment).
* The patient will be compliant to the study schedule, in the discretion of the investigator.

Exclusion Criteria:

* The patient has tuberculosis which is assessed to receive high dose rifampicin according to the local standard of care.
* The patient started current TB treatment more than 4 weeks ago.
* The patient has TB meningitis.
* The patient is in a coma.
* Circumstances that raise doubt about free, uncoerced consent to study participation (e.g. in a prisoner or mentally handicapped person)
* The patient is not able to give consent personally.
* Poor general condition or comorbidities where delay in treatment cannot be tolerated or death within three months is likely. Or if there is concurrent treatment that may interfere.
* The patient is pregnant or breast-feeding.
* Patient infected with a rifampicin-resistant strain of M. tuberculosis.
* Known allergy or intolerance for rifamycins.
* The participant has a known or suspected, current alcohol or drug or amphetamine abuse, that is, in the opinion of the investigator, sufficient to compromise the safety or cooperation of the patient.
* The patient has a known allergy or intolerance, or concomitant disorders or conditions for which rifamycins or other standard TB treatment drugs are contraindicated.
* The patient has had treatment with any other investigational drug within 1 month prior to enrolment, or enrolment into other clinical (intervention) trials is planned in the upcoming 6 months
* Laboratory: at screening one or more of the following abnormalities were observed for the patient in screening laboratory:

  * Serum amino aspartate transferase (AST) and/or serum alanine aminotransferase (ALT) activity \>3x the upper limit of normal
  * Serum total bilirubin level \>2.5 times the upper limit of normal
  * Creatinine clearance (CrCl) level lower than 30 mls/min
* Acute or severe or life-threatening liver disease induced by drugs in the past
* The patient has a chronic disorder such as liver disease or renal disease.
* The patient has icterus.
* Previous anti-TB treatment: the patient ended a previous TB treatment (episode) within last 3 months.

Where it's running

• ASL Città di Torino
  Turin, Italy Recruiting
• Radboud University Medical Centre
  Nijmegen, Netherlands Recruiting

Study contacts

• Principal investigator: Martin Boeree — Radboud University Medical Center
• Study coordinator: Jodie Schilkdraut, PhD
• Email: Jodie.schildkraut@radboudumc.nl
• Phone: +31 629677680

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• FAP PET/CT in adults with pulmonary TB

  This early-phase study tests whether a FAP PET/CT scan can map lung fibrosis in adults with pulmonary TB before starting treatment and after cure.

  Recruiting Early Phase 1 University of Pennsylvania · Philadelphia, Pennsylvania · NCT07830771

• Sorfequiline-based regimens for adults with newly diagnosed drug-sensitive pulmonary TB

  This study tests two sorfequiline-containing regimens, each with pretomanid and linezolid, to see if they are safe and effective in adults with newly diagnosed drug-sensitive pulmonary TB.

  Recruiting at 6 sites Phase 2 Global Alliance for TB Drug Development · Wentworth, Durban and 11 other locations · NCT07672405

• Digital health tool to help more people start TB preventive therapy

  A digital health approach is being tested to see if it helps household and close contacts of people with drug-sensitive pulmonary TB start TB preventive therapy better.

  Recruiting at 8 sites Arba Minch University · Arba Minch, South Ethiopia and 13 other locations · NCT07313995

• Ear acupuncture to reduce nausea and vomiting from tuberculosis medicines

  This trial will test whether press-needle ear acupuncture can reduce nausea and vomiting in people taking medicines for pulmonary tuberculosis.

  Recruiting Universitas Indonesia · Jakarta, Jakarta Timur · NCT07271225

• 18F-FAPI-74 PET imaging for lung fibrosis in tuberculosis

  This project tries to see if 18F-FAPI-74 PET scans can detect lung fibrosis in adults with active or recently treated tuberculosis.

  Recruiting Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio · NCT07077213

• Blood TB DNA test to track treatment progress

  This project will test whether levels of TB-derived cell-free DNA in the blood can track treatment response in adults newly diagnosed with tuberculosis.

  Recruiting University of Oxford · Tak · NCT06845618

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.